Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. (2021)
Attributed to:
Predictive biomarkers of response to DNA repair targeting agents in sporadic prostate cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/2159-8290.cd-21-0007
PubMed Identifier: 34045297
Publication URI: http://europepmc.org/abstract/MED/34045297
Type: Journal Article/Review
Volume: 11
Parent Publication: Cancer discovery
Issue: 11
ISSN: 2159-8274